SEIKAGAKU CORPORATION Patent applications |
Patent application number | Title | Published |
20160115511 | HEPAROSAN-GLUCURONIC ACID-5-EPIMERASE, AND METHOD FOR PRODUCING POLYSACCHARIDE USING SAME - To provide a polypeptide having heparosan-glucuronate 5-epimerase activity, whereby means for producing a polysaccharide in which hexuronic acid residues has been epimerized is provided. Through screening of | 04-28-2016 |
20160061838 | PRE-TREATMENT AGENT AND PRE-TREATMENT METHOD FOR ANTITHROMBIN III TO BE SUBJECTED TO LIMULUS TEST - To provide means for reducing reaction interference observed when AT III is subjected to limulus test, whereby the limulus test of antithrombin III can be carried out at high accuracy. Reaction interference observed when AT III is subjected to limulus test can be reduced by subjecting AT III to a protein inactivation treatment in the co-presence of a divalent metal salt. | 03-03-2016 |
20150307864 | NOVEL RECOMBINANT FACTOR C AND METHOD FOR PRODUCING THE SAME, AND METHOD FOR MEASURING ENDOTOXIN - To provide a method for producing a horseshoe crab recombinant Factor C. The horseshoe crab recombinant Factor C is produced through expression thereof by use of mammalian cells such as CHO DG44 and HEK293 as host cells. | 10-29-2015 |
20150283169 | PHARMACEUTICAL AGENT HAVING LONG-LASTING EFFECT OF TREATING ARTHRITIC DISORDERS - The present invention relates to an injection solution for intra-articular administration for treating arthritic disorders comprising a cross-linked hyaluronic acid derivative wherein part of functional groups of a hyaluronic acid are cross-linked with a cross-linking group to the extent of 0.6 to 15% of cross-linking extent as an active ingredient in an amount having a long-lasting analgesic effect and a pharmaceutically acceptable carrier, and an analgesic composition for suppressing a cartilage degeneration caused by arthritic disorders or a composition for suppressing a cartilage degeneration or an inflammation of synovium caused by arthritic disorders each comprising the cross-linked hyaluronic acid derivative and a pharmaceutically acceptable carrier. | 10-08-2015 |
20150196574 | AGENT FOR APPLYING TO MUCOSA AND METHOD FOR THE PRODUCTION THEREOF - An agent for applying to mucosa capable of persistently exerting a therapeutic effect on disorders such as inflammation and lesions in the mucosa even by a lower frequency of administration because the agent can stay at a diseased site for a long period of time by exhibiting a high staying properly in a mucosal epithelial layer is provided, said agent for application to mucosa containing glycosaminoglycan (GAG) into which a hydrophobic group is introduced via a binding chain, as an active ingredient. | 07-16-2015 |
20150094280 | PHARMACEUTICAL AGENT HAVING LONG-LASTING EFFECT OF TREATING ARTHRITIC DISORDERS - The present invention relates to an injection solution for intra-articular administration for treating arthritic disorders comprising a cross-linked hyaluronic acid derivative wherein part of functional groups of a hyaluronic acid are cross-linked with a cross-linking group to the extent of 0.6 to 15% of cross-linking extent as an active ingredient in an amount having a long-lasting analgesic effect and a pharmaceutically acceptable carrier, and an analgesic composition for suppressing a cartilage degeneration caused by arthritic disorders or a composition for suppressing a cartilage degeneration or an inflammation of synovium caused by arthritic disorders each comprising the cross-linked hyaluronic acid derivative and a pharmaceutically acceptable carrier. | 04-02-2015 |
20140296505 | COMPOSITIONS AND METHODS FOR BACTERIAL PRODUCTION OF CHONDROITIN - The invention relates to the field of recombinant DNA technology for the production of chondroitin, including the production of chondroitin sulfate via a combination of recombinant bacterial fermentation and post-fermentation sulfation. | 10-02-2014 |
20140024062 | AGENT FOR MEASURING ENDOTOXIN - A method for rapidly and highly sensitively measuring endotoxin is provided. Endotoxin is measured using an endotoxin-measuring agent comprising the proteins (1) to (3) below, each of which is a recombinant protein obtainable by being expressed using insect cells as a host: (1) a factor C derived from | 01-23-2014 |
20130309701 | NUCLEIC ACID FRAGMENT ENCODING A HORSESHOE CRAB-DERIVED PRO-CLOTTING ENZYME - Objects of the present invention are to provide a DNA fragment encoding a | 11-21-2013 |
20130266555 | THERAPEUTIC AGENT FOR DISC HERNIATION - The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk. | 10-10-2013 |
20130230509 | AGENT FOR NEUROPATHIC PAIN - An object of the present invention is to provide a substance which can be used as an active ingredient for improving neuropathic pain having a novel mechanism of action different from those of currently available agents and, therefore, provide an improving agent for neuropathic pain which rarely interacts with currently available agents and also does not have adverse reactions similar to those of currently available agents. An improving agent for neuropathic pain due to a hyperalgesic response of the present invention as a means for resolution is characterized by comprising, as an active ingredient, a lyase (an elimination enzyme) which has an activity of degrading a chondroitin sulfate chain of a chondroitin sulfate proteoglycan, and is typified by chondroitinase ABC which selectively removes chondroitin sulfate and dermatan sulfate of a proteoglycan. | 09-05-2013 |
20130196943 | NOVEL CHONDROITIN SULFATE HAVING DECREASED MOLECULAR WEIGHT AND USE THEREOF - A chondroitin sulfate having a decreased molecular weight which has utilization as an inhibitor of peritoneal disorder caused by long-term use of a peritoneal dialysis fluid containing glucose or a polysaccharide thereof as an osmotic agent, utilization as an osmotic agent in a peritoneal dialysis fluid, and the like. The chondroitin sulfate having a decreased molecular weight of the present invention as a means for achieving the object is characterized by having a weight average molecular weight of from 1000 to 20000 and containing a constituent disaccharide unit represented by the following structural formula in an amount of from 65% to 100% (molar ratio) of the total: | 08-01-2013 |
20130164276 | AGENT FOR DYSFUNCTION DUE TO NEUROPATHY AND Rho KINASE ACTIVATION INHIBITOR - An object of the present invention is to provide a substance which is able to be an active ingredient for the improvement of dysfunction caused by nerve damage. An improving agent for dysfunction due to nerve damage of the present invention as a means for resolution thereof is characterized in that it comprises an endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosamide bond in a keratan sulfate backbone as an active ingredient. When the improving agent of the present invention is administered, clinical improvement is achieved in motor neuron dysfunction and sensory neuron dysfunction such as neuropathic pain represented by a pain caused by allodynia and hyperalgesic reaction of the object to be treated. | 06-27-2013 |
20120291789 | MEDICAL COMPOSITION FOR PROTUBERANCE OF EPITHELIUM - A medical composition for protuberance of epithelium, which comprises a solution comprising a polysaccharide or a medically acceptable salt thereof, wherein the solution has a viscosity of: (1) from 50 to 500 mPa·s at a shear rate of from 7.7 to 10.0 s | 11-22-2012 |
20120142629 | PHARMACEUTICAL COMPOSITION FOR RELIEVING PAIN - The present invention relates to a pharmaceutical composition for relieving pain in a joint disease, including a hyaluronic acid and a pharmaceutically acceptable carrier, in which the hyaluronic acid is cross-linked by cyclizing a double bond in the moiety of a cinnamic acid in a partially amidated hyaluronic acid represented by Formula (1): [Ar—CH═CH—COO—(CH | 06-07-2012 |
20120055780 | POLYSACCHARIDE PSEUDO-SPONGE - A photocrosslinked polysaccharide pseudo-sponge exhibiting a low swelling property and a high degradation ability in vivo while retaining a suitable strength. The polysaccharide pseudo-sponge is produced by a crosslinking reaction of a photoreactive polysaccharide obtained by introducing a photoreactive group into a polysaccharide, and exhibits a low swelling property and a blue dextran-low dyeaffinity. | 03-08-2012 |
20110318759 | METHOD FOR ASSAYING KERATAN SULFATE, ASSAY KIT THEREFOR AND METHOD FOR DETECTING JOINT DISEASE BY USING THE SAME - The inventions provides a method for immunologically determining a keratan sulfate level which method includes bringing an anti-keratan sulfate monoclonal antibody into contact with a biological sample, the anti-keratan sulfate monoclonal antibody exhibiting a relative reaction specificity between keratan sulfate-I and keratan sulfate-II represented by IC50 | 12-29-2011 |
20110288048 | PROMOTER FOR HARD TISSUE FORMATION - The present invention provides an agent which induces acceleration of hard tissue formation, acceleration of cell differentiation and increase in cellular alkaline phosphatase activity, by directly acting on the cell. Specifically, it provides a hard tissue formation promoter, a cell differentiation inducer and a cellular alkaline phosphatase activity reinforcing agent comprising, as an active ingredient, a glycosaminoglycan or a salt thereof that keeps sulfate group and has the characteristics of the following (1) and (2): (1) a basic structure is a disaccharide repeating structure consisting of a hexuronic acid residue and a glucosamine residue, (2) one or less of the position among a 2-position hydroxyl group of a hexuronic acid residue, a 6-position hydroxyl group of a glucosamine residue and a 2-position amino group of the glucosamine residue in the basic structure of the aforementioned (1) does not have the sulfate group. In this connection, it is preferable that the hexuronic acid residue is a glucuronic acid residue or an iduronic acid residue. | 11-24-2011 |
20110275137 | IMPROVING AGENT FOR NEUROPATHIC PAIN - An object of the present invention is to provide a substance which can be used as an active ingredient for improving neuropathic pain having a novel mechanism of action different from those of currently available agents and, therefore, provide an improving agent for neuropathic pain which rarely interacts with currently available agents and also does not have adverse reactions similar to those of currently available agents. An improving agent for neuropathic pain due to a hyperalgesic response of the present invention as a means for resolution is characterized by comprising, as an active ingredient, a lyase (an elimination enzyme) which has an activity of degrading a chondroitin sulfate chain of a chondroitin sulfate proteoglycan, and is typified by chondroitinase ABC which selectively removes chondroitin sulfate and dermatan sulfate of a proteoglycan. | 11-10-2011 |
20110256563 | METHOD FOR DETECTING LYSOSOMAL STORAGE DISEASES - A method for detecting lysosomal storage diseases including the steps of performing an assay for a single species of glycosaminoglycan contained in a specimen and correlating results of the assay with lysosomal storage diseases. A body fluid such as urine or blood can be employed as a specimen. The assay can be performed by use of a polypeptide that is capable of specifically binding to a glycosaminoglycan-containing molecule. The polypeptide may be an antibody, or a polypeptide having an antigen-binding site of an antibody. | 10-20-2011 |
20110224169 | HYALURONIC ACID OLIGOSACCHARIDE FRACTIONS AND DRUGS CONTAINING THE SAME - A method for promoting expression of a heat shock protein, or for inhibiting cell injury or cell death, or for treating a disease for which cell or tissue protection is desired, or for promoting production of IL-10, or for inhibiting production of IL-8, by administering an effective amount of a fraction containing a hyaluronic acid tetrasaccharide comprising four saccharide residues and having certain physicochemical properties or by administering an effective amount of an isolated and substantially pure tetrasaccharide of formula (1) described in the application. Methods for preserving an organ. | 09-15-2011 |
20110207695 | AGENT FOR APPLYING TO MUCOSA AND METHOD FOR THE PRODUCTION THEREOF - An agent for applying to mucosa capable of persistently exerting a therapeutic effect on disorders such as inflammation and lesions in the mucosa even by a lower frequency of administration because the agent can stay at a diseased site for a long period of time by exhibiting a high staying property in a mucosal epithelial layer is provided, said agent for application to mucosa containing glycosaminoglycan (GAG) into which a hydrophobic group is introduced via a binding chain, as an active ingredient. | 08-25-2011 |
20110201570 | NUCLEUS PULPOSUS FILLER - The present invention provides a nucleus pulposus filler or the like which is to be packed into an area in deformed intervertebral disc wherein normal nucleus should be located and can be stabley maintained for a long time More preferably, the present invention provides a nucleus pulposus filler comprising a crosslinked chondroitin sulfate as an active ingredient. The photocrosslinked chondroitin sulfate is preferably the following one: a photocrosslinked chondroitin sulfate obtainable by freezing a photoreactive chondroitin sulfate-containing solution comprising: a photoreactive chondroitin sulfate to which a photoreactive group is bound; an aqueous solvent capable of dissolving the photoreactive chondroitin sulfate; and any one substance selected from the group consisting of an alcohol having aqueous solvent miscibility, a surfactant, and a cheleting agent; irradiating the resulting frozen product with light; and then melting the frozen product. The filler can be provided as a kit by packing it into a container from which the filler can be pushed out. | 08-18-2011 |
20110195476 | MODIFIED CHONDROITIN SYNTHASE POLYPEPTIDE AND CRYSTAL THEREOF - Disclosed are: (A) a polypeptide consisting of the amino acid sequence of SEQ ID NO:2, or (B) a polypeptide comprising an amino acid sequence of SEQ ID NO:2 including deletion, substitution or addition of one or several amino acid residues and having chondroitin synthase activity; a nucleic acid encoding the polypeptide; a method for producing the polypeptide, comprising at least the steps of: (1) expressing the nucleic acid to produce the polypeptide; and (2) collecting the polypeptide produced in the step (1); and a crystal of the polypeptide. The crystal may be a monoclinic or tetragonal crystal. | 08-11-2011 |
20110151492 | METHOD OF DETECTING ARTICULAR CARTILAGE DEGENERATION OR DAMAGE - An object of the present invention is to provide a detection method capable of detecting articular cartilage degeneration or damage in which the abnormality cannot be detected in a radiograph in a simple method and with high accuracy, a method of evaluating the rate of progression of articular cartilage degeneration or damage, and the like. | 06-23-2011 |
20110139830 | TIGHT-SEALING CAP FOR LIQUID DRUG-EXPELLING PART - Provided is a tight-sealing cap for the liquid drug-expelling part of a syringe that not only minimizes the space that creates reduced pressure, which is a cause of leakage, but is also easy to remove because it is easily twisted off, easily deformable and easily admits air for releasing the vacuum when removed, and that can prevent leaking of a liquid drug from a luer nozzle. The cap is made of an elastic material, and the following means are used in the cap, which is configured from a thick upper surface part, an outer tubular part that is formed below the periphery thereof, and an inner tubular part that is formed inside the same. First, the inner tubular part is formed so that the tip of the luer nozzle can be inserted tightly into the same, and the luer nozzle can be tightly sealed at the site of contact thereof. Second, the outer tubular part is formed so that it contacts the luer lock closely therein and can seal the luer lock tightly at the site of contact thereof. Third, the length of the site of contact between the outer tubular part and the luer lock is shorter than the length of the site of contact between the inner tubular part and the luer nozzle. | 06-16-2011 |
20110124082 | MUTANT GLYCOPROTEIN RESISTANT TO MODIFICATION WITH ASPARAGINE-LINKED SUGAR CHAIN - To obtain a mutant protein of an asparagine-linked glycoprotein, which has no N-linked sugar chain under ordinary circumstance, and remains a physiological activity of the glycoprotein before the mutation was introduced, at least one of the amino acids contained in the amino acid sequence motif (I) and/or (II) in the polypeptide of the asparagine-linked glycoprotein is substituted into another amino acid: (I) Asn Xa1 Xa2 (II) Xa3 Val Gly Asn Xa1 Xa2. In amino acid sequence motif (I) and (II), Xa1 represents an amino acid other than Pro, Xa2 represents Thr or Ser and Xa3 represents His or Asp. | 05-26-2011 |
20110098455 | Crosslinked polysaccharide sponge - A process for producing a polysaccharide sponge comprises the steps of (A) freezing a photoreactive polysaccharide solution, and (B) irradiating the frozen photoreactive polysaccharide solution with light to crosslink the photoreactive polysaccharide, thereby obtaining the polysaccharide sponge. The process includes simplified steps requiring no removal of solvent, and has such an advantage that impurities are easily removed therefrom. | 04-28-2011 |
20110083991 | HYALURONIC ACID DERIVATIVE AND DRUG CONTAINING THE SAME - A hyaluronic acid derivative in which an anti-inflammatory drug is bound to hyaluronic acid through a covalent bond via a spacer having a biodegradable region, and a production process thereof. | 04-14-2011 |
20110059508 | IMPROVING AGENT FOR DYSFUNCTION DUE TO NEUROPATHY AND RHO KINASE ACTIVATION INHIBITOR - An object of the present invention is to provide a substance which is able to be an active ingredient for the improvement of dysfunction caused by nerve damage. An improving agent for dysfunction due to nerve damage of the present invention as a means for resolution thereof is characterized in that it comprises an endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosamide bond in a keratan sulfate backbone as an active ingredient. When the improving agent of the present invention is administered, clinical improvement is achieved in motor neuron dysfunction and sensory neuron dysfunction such as neuropathic pain represented by a pain caused by allodynia and hyperalgesic reaction of the object to be treated. | 03-10-2011 |
20110053885 | PHARMACEUTICAL AGENT HAVING LONG-LASTING EFFECT OF TREATING ARTHRITIC DISORDERS - The present invention relates to an injection solution for intra-articular administration for treating arthritic disorders comprising a cross-linked hyaluronic acid derivative wherein part of functional groups of a hyaluronic acid are cross-linked with a cross-linking group to the extent of 0.6 to 15% of cross-linking extent as an active ingredient in an amount having a long-lasting analgesic effect and a pharmaceutically acceptable carrier, and an analgesic composition for suppressing a cartilage degeneration caused by arthritic disorders or a composition for suppressing a cartilage degeneration or an inflammation of synovium caused by arthritic disorders each comprising the cross-linked hyaluronic acid derivative and a pharmaceutically acceptable carrier. | 03-03-2011 |
20110033939 | METHOD OF MEASURING LIPOARABINOMANNAN AND APPLICATION THEREOF - A method for measuring LAM and a method for detecting an acid-fast bacterium, which comprise at least a step of allowing a | 02-10-2011 |
20110008312 | RADICAL THERAPEUTIC AGENT FOR KELOID AND HYPERTROPHIC SCAR - An effective therapeutic agent for keloids and/or hypertrophic scars is provided. Specifically, an elastic fiber regenerating agent consisting of chondroitinase ABC derived from | 01-13-2011 |
20100286085 | NOVEL CHONDROITIN SULFATE HAVING DECREASED MOLECULAR WEIGHT AND USE THEREOF - An object of the present invention is to provide a chondroitin sulfate having a decreased molecular weight which has utilization as an inhibitor of peritoneal disorder caused by long-term use of a peritoneal dialysis fluid containing glucose or a polysaccharide thereof as an osmotic agent, utilization as an osmotic agent in a peritoneal dialysis fluid, and the like. The chondroitin sulfate having a decreased molecular weight of the present invention as a means for achieving the object is characterized by having a weight average molecular weight of from 1000 to 20000 and containing a constituent disaccharide unit represented by the following structural formula in an amount of from 65 o to 100% (molar ratio) of the total. | 11-11-2010 |
20100168057 | FUNGAL GROWTH INHIBITOR - A very safe and useful agent for inhibiting fungal growth and the like are provided by the present invention. Specifically, the present invention provides (1) an agent for inhibiting fungal growth comprising hyaluronic acid or a salt thereof excluding a heavy metal salt as the active ingredient, and a method for inhibiting fungal growth, which comprises at least a step of allowing hyaluronic acid or a salt thereof excluding a heavy metal salt to contact with a fungus, (2) an agent for reinforcing activity of inhibiting fungal growth possessed by a cell, which comprises a DNA encoding a hyaluronic acid synthase as the active ingredient, (3) a method for reinforcing activity of inhibiting fungal growth of a cell, which comprises at least a step of transfecting a DNA encoding a hyaluronic acid synthase into the cell, and (4) a method for inhibiting fungal growth, which comprises at least a step of allowing a cell transfected with a DNA encoding a hyaluronic acid synthase to contact with a fungus. | 07-01-2010 |
20100151532 | CHONDROITIN-PRODUCING BACTERIUM AND METHOD OF PRODUCING CHONDROITIN - Chondroitin is produced by culturing a UDP-glucuronic acid-producing bacterium transfected with a kfoA gene derived from | 06-17-2010 |
20100112668 | Method For Producing Factor G Derived From HorseShoe Crab - The invention provides a virus harboring a DNA encoding a subunit of | 05-06-2010 |
20100068759 | MODIFIED CHONDROITIN SYNTHASE POLYPEPTIDE AND CRYSTAL THEREOF - Disclosed are: (A) a polypeptide consisting of the amino acid sequence of SEQ ID NO:2, or (B) a polypeptide comprising an amino acid sequence of SEQ ID NO:2 including deletion, substitution or addition of one or several amino acid residues and having chondroitin synthase activity; a nucleic acid encoding the polypeptide; a method for producing the polypeptide, comprising at least the steps of: (1) expressing the nucleic acid to produce the polypeptide; and (2) collecting the polypeptide produced in the step (1); and a crystal of the polypeptide. The crystal may be a monoclinic or tetragonal crystal. | 03-18-2010 |
20100041071 | METHOD FOR DETERMINATION OF MOLECULAR WEIGHT OF HYALURONIC ACID - A method of measuring a molecular weight of hyaluronic acid, comprising at least reacting hyaluronic acid in a sample containing the hyaluronic acid with a hyaluronic acid-binding protein to measure an amount of the hyaluronic acid-binding protein that is bound to the hyaluronic acid in the sample or a value that reflects the amount. | 02-18-2010 |
20090325899 | MEDICAL COMPOSITION FOR PROTUBERANCE OF EPITHELIUM - A medical composition for protuberance of epithelium, which comprises a solution comprising a polysaccharide or a medically acceptable salt thereof, wherein the solution has a viscosity of: (1) from 50 to 500 mPa·s at a shear rate of from 7.7 to 10.0 s | 12-31-2009 |
20090291914 | HYALURONIC ACID OLIGOSACCHARIDE FRACTIONS AND DRUGS CONTAINING THE SAME - A method for promoting expression of a heat shock protein, or for inhibiting cell injury or cell death, or for treating a disease for which cell or tissue protection is desired, or for promoting production of IL-10, or for inhibiting production of IL-8, by administering an effective amount of a fraction containing a hyaluronic acid tetrasaccharide comprising four saccharide residues and having certain physicochemical properties or by administering an effective amount of an isolated and substantially pure tetrasaccharide of formula (1) described in the application. Methods for preserving an organ. | 11-26-2009 |
20090291459 | HYBRIDOMA CAPABLE OF PRODUCING ANTI-DECTIN-1 MONOCLONAL ANTIBODY - A hybridoma capable of producing a monoclonal antibody against dectin-1, and a monoclonal antibody which specifically reacts with dectin-1. | 11-26-2009 |
20090281051 | CARBA-SUGAR AMINE DERIVATIVE AND GLYCOLIPID METABOLIC DISORDER TREATING AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT - A carba-sugar amine derivative represented by the following formula (1) or (2) is used as the active ingredient of a β-galactosidase inhibitor or a glycolipid metabolic disorder treating agent. | 11-12-2009 |
20090280505 | METHOD FOR DETECTING LYSOSOMAL STORAGE DISEASES - A method for detecting lysosomal storage diseases including the steps of performing an assay for a single species of glycosaminoglycan contained in a specimen and correlating results of the assay with lysosomal storage diseases. A body fluid such as urine or blood can be employed as a specimen. The assay can be performed by use of a polypeptide that is capable of specifically binding to a glycosaminoglycan-containing molecule. The polypeptide may be an antibody, or a polypeptide having an antigen-binding site of an antibody. | 11-12-2009 |
20090280502 | ANTI-2-O-DESULFATED ACHARAN SULFATE ANTIBODY AND ITS APPLICATION - An antibody that reacts with 2-O-desulfated acharan sulfate, a hybridoma that produces the antibody, a detection method and a detection kit to which the antibody is applied are disclosed. The antibody that reacts with 2-O-desulfated acharan sulfate can be produced by immunizing a mammal using as an antigen a substance obtained by chemically bonding a protein to 2-O-desulfated acharan sulfate. | 11-12-2009 |
20090275048 | ANTI-ACHARAN SULFATE ANTIBODY AND ITS APPLICATION - An anti-acharan sulfate antibody, a hybridoma that produces the antibody, a detection method and a detection kit to which the antibody is applied are disclosed. The anti-acharan sulfate antibody can be produced by immunizing a mammal using as an antigen a substance obtained by chemically bonding a protein to acharan sulfate. | 11-05-2009 |
20090269802 | ALPHA 1,4-GALACTOSYLTRANSFERASE AND DNA ENCODING THEREOF - The object of the present invention is to provide α1,4-galactosyltransferase to transfer a galactose residue to C4 position of galactose residue of lactosylceramide or galactosylceramide, and DNA coding for the enzyme. | 10-29-2009 |
20090263867 | LONG-CHAIN CHONDROITIN SUGAR CHAIN AND METHOD FOR PRODUCING THE SAME AND METHOD FOR PROMOTING SYNTHESIS OF CHONDROITIN - A method for producing a chondroitin sugar chain comprises at least the following step: a step of allowing “a glucuronic acid donor”, “an N-acetyl galactosamine donor”, “a sugar receptor” and “a bacterial cell enzyme which synthesizes chondroitin” to coexist in a reaction system in the presence of a surfactant. Here, the surfactant is preferably selected from n-nonyl-β-D-thiomaltopyranoside, sucrose monocaproate and sucrose monolaurate. The chondroitin sugar chain has all the following properties 1) to 3): 1) a weight average molecular weight: 50,000 or more when it is measured by gel filtration chromatography, 2) it is completely degraded to disaccharides with chondroitinase ABC, 3) when the sugar chain is decomposed with chondroitinase ABC and the decomposed products are subjected to a disaccharide analysis, substantially all of them correspond to an unsaturated disaccharide unit of chondroitin. | 10-22-2009 |
20090233336 | PROCESS FOR PRODUCING CHONDROITIN - A method for producing a chondroitin (CH) with a desired sugar chain length; a method for producing a fraction containing a CH with a substantially single sugar chain length; etc. There is provided a method for producing a CH with desired sugar chain length, comprising alternately performing the steps (a) allowing a receptor substrate having a glucuronic acid residue at its non-reducing end (when this step is performed after the step (b), sugar chain obtained by the step (b)), an N-acetylgalactosamine donor and an N-acetylgalactosamine transferase to coexist in a reaction system and (b) allowing a receptor substrate having an N-acetylgalactosamine residue at its non-reducing end (when this step is performed after the step (a), sugar chain obtained by the step (a)), a glucuronic acid donor and a glucuronic acid transferase to coexist in a reaction system. | 09-17-2009 |
20090209733 | THERAPEUTIC AGENT FOR RHEUMATOID ARTHRITIS - A therapeutic agent for rheumatoid arthritis, particularly a therapeutic agent for ameliorating an inflammatory symptom or bone deformity in rheumatoid arthritis, which comprises an antibody that binds to a hepatocyte growth factor receptor as an active ingredient. | 08-20-2009 |
20090208995 | PRO-CLOTTING ENZYME, AND METHOD FOR DETECTION OF ENDOTOXIN OR (1-3)-BETA-D-GLUCAN USING THE SAME - Objects of the present invention are to provide a DNA fragment encoding a | 08-20-2009 |
20090198213 | METHOD OF OPHTHALMIC SURGERY AND KIT THEREFOR - A method of micro-incision ophthalmic surgery, comprising, in the order mentioned, the steps of: | 08-06-2009 |
20090156805 | Cycloalkane Carboxamide Derivatives and Production Process of Same - Novel cycloalkane carboxamide derivatives having an action that selectively inhibits cathepsin K, and a production process thereof, are provided. | 06-18-2009 |
20090155851 | NOVEL PROCESS FOR PREPARATION OF CHONDROITIN FRACTION - Provided are a method for producing a fraction containing more than 50% of CH represented by the general formula (1), which comprises at least the step of allowing a glucuronic acid donor, an N-acetylgalactosamine donor, a saccharide receptor, a chondroitin polymerase derived from the | 06-18-2009 |
20090137799 | Cycloalkylcarbonylamino Acid Ester Derivative and Process for Producing The Same - Cycloalkylcarbonylamino acid ester derivatives, which are raw material intermediates for a novel cycloalkane carboxamide derivative having an action that selectively inhibits cathepsin K, and a production process thereof, are provided. | 05-28-2009 |
20090137482 | BIOLOGICALLY ACTIVE PEPTIDE AND AGENT CONTAINING THE SAME - A peptide having any one of the amino acid sequences of SEQ ID NO: 1 or 13, preferably a peptide having any one of the amino acid sequences of SEQ ID NOS: 2 to 9 or a peptide having any one of the amino acid sequences of SEQ ID NOS: 10 and 15 to 17, is used as an active ingredient of an agent for promoting growth or differentiation of cells such as osteoblasts, chondroblasts, cementoblasts, bone marrow-derived mesenchymal stem cells and periodontal ligament-derived cells. | 05-28-2009 |
20090131661 | Oxazolone Derivatives - Novel raw material compounds are provided that are useful for producing novel cycloalkane carboxamide derivatives having cathepsin K inhibitory action. | 05-21-2009 |
20090117661 | METHOD OF ELIMINATING REACTIVITY OF LIPOARABINOMANNAN AND APPLICATION OF THE SAME - A method of eliminating the reactivity of lipoarabinomannan contained in a sample to a | 05-07-2009 |
20090111983 | Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same - Cycloalkylcarbonylamino acid derivatives, which are raw material intermediates of a novel cycloalkane carboxamide derivative that selectively inhibits cathepsin K, and a production process thereof, are provided. | 04-30-2009 |
20090104678 | METHOD OF PRODUCING POLYSACCHARIDE DERIVATIVES - A polysaccharide derivative having a high solubility in an aqueous solvent is produced. The production method of the present invention uses a compound shown by the general formula (1) as a condensing agent and allows a polysaccharide having a carboxyl group to react with an an organic compound having a functional group capable of condensing with the carboxyl group to prepare the polysaccharide derivative: | 04-23-2009 |
20090104627 | METHOD FOR DETERMINATION OF ENZYMATIC ACTIVITY - A novel modified polysaccharide, a solid phase to which the polysaccharide is adhered, methods for detecting N-deacetylase activity, N-sulfotransferase activity and N-deacetylase/N-sulfotransferase activity in a sample which utilizes said solid phase, and detection kits thereof. | 04-23-2009 |
20090012278 | Promoter For Hard Tissue Formation - The present invention provides an agent which induces acceleration of hard tissue formation, acceleration of cell differentiation and increase in cellular alkaline phosphatase activity, by directly acting on the cell. Specifically, it provides a hard tissue formation promoter, a cell differentiation inducer and a cellular alkaline phosphatase activity reinforcing agent comprising, as an active ingredient, a glycosaminoglycan or a salt thereof that keeps sulfate group and has the characteristics of the following (1) and (2): (1) a basic structure is a disaccharide repeating structure consisting of a hexuronic acid residue and a glucosamine residue, (2) one or less of the position among a 2-position hydroxyl group of a hexuronic acid residue, a 6-position hydroxyl group of a glucosamine residue and a 2-position amino group of the glucosamine residue in the basic structure of the aforementioned (1) does not have the sulfate group. In this connection, it is preferable that the hexuronic acid residue is a glucuronic acid residue or an iduronic acid residue. | 01-08-2009 |
20090011448 | PRETREATMENT AGENT FOR LIMULUS TEST - A pretreatment agent for a sample to be subjected to Limulus assay comprising an alkali metal sulfate and/or an alkaline earth metal sulfate wherein the sulfate(s) has a final concentration of 20 mM or more when the sulfate(s) is allowed to contact with the sample, or an alkali metal halide and/or an alkaline earth metal halide wherein the halide(s) has a final concentration of from 0.4 M to 1.2 M or less when the halide(s) is allowed to contact with the sample, or a kit for Limulus assay reagent comprising thereof as a composing article. | 01-08-2009 |
20080306024 | METHOD FOR MICRO-INCISION CATARACT SURGERY, A METHOD OF EVALUATION OF A VISCOELASTIC MATERIAL , A COMPOSITION FOR EVALUATION OF A VISCOELASTIC MATERIAL AND A METHOD FOR EVALUATION USING THE COMPOSITION - A method for micro-incision cataract surgery, wherein a solution containing hyaluronic acid having a weight average molecular weight of from 600,000 to 1,200,000 or a salt thereof is injected into the anterior chamber, and flow rate of a perfusion liquid in the anterior chamber is set to about be 35 to 40 mL/min or less, a method for evaluating retentivity of a viscoelastic material, which uses a device consisting of a micro-flare ultrasonic chip arranged in water, a sleeve which covers said chip and a hollow cylinder into which said chip is inserted, and a composition for evaluation of retentivity of a viscoelastic material, which comprises at least said viscoelastic material and a fluorescent granule, are provided. | 12-11-2008 |